Bladder Non-Urothelial Carcinoma

subtype

Identifier: CI-CAN-00008756
Entity page: /cancer/bladder-non-urothelial-carcinoma ↗
Edges: 37

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Bladder Non-Urothelial Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 21show all (up to 200)
→ investigated in trials for	Carboplatinsmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Bladder Non-Urothelial Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatin

Bladder Non-Urothelial Carcinoma studied in …STUDIED_INderived10 of 16show all (up to 200)
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped CURATED_BROADER · 16 trials mapped (7 active)	—	—	Bladder Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02496208Phase 1 · active not recruiting Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 16 trials mapped (7 active)	—	—	Bladder Small Cell Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06041503Phase 2 · recruiting Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) · condition mapped ALIAS · 16 trials mapped (7 active)	—	—	Bladder Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06161532Phase 2 · recruiting Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... · condition mapped ALIAS · 16 trials mapped (7 active)	—	—	Bladder Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05756569Phase 2 · recruiting Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology · condition mapped ONTOLOGY_EXACT · 16 trials mapped (7 active)	—	—	Bladder Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02834013Phase 2 · active not recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped CURATED_BROADER · 16 trials mapped (7 active)	—	—	Bladder Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03582475Phase 1 · active not recruiting Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate · condition mapped ONTOLOGY_EXACT · 16 trials mapped (7 active)	—	—	Bladder Small Cell Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03912818Phase 2 · terminated Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer · condition mapped CURATED_BROADER · 16 trials mapped (7 active)	—	—	Bladder Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01954173NA · terminated Adjuvant Radiation for High Risk Bladder Cancer · condition mapped ALIAS · 16 trials mapped (7 active)	—	—	Bladder Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03430895Phase 2 · completed Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract · condition mapped ALIAS · 16 trials mapped (7 active)	—	—	Bladder Adenocarcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains